

Non-fermenting Gram-Negative Rods

Neisseria spp. and *Moraxella* spp.

SUSAN HARRINGTON, PHD D (ABMM), MLS (ASCP)^{CM}

2022

Non-fermenters

Characteristics

- Aerobic metabolism
- Non-spore forming
- Do not **ferment** glucose; Utilize carbohydrates oxidatively or do not use carbohydrates as energy source.

Classical Taxonomic Tools

- Glucose metabolism - oxidative/assacharolytic
- Cytochrome oxidase
- Growth on MacConkey agar
- Gram stain morphology
- Colony morphology and pigment production
- Motility/arrangement of flagella. Requires flagellar stains.

Glucose Fermentation: The O/F Test



Uninoculated tubes

(Left has oil on top i.e. anaerobic; the right is open to oxygen)



Oxidative metabolism

Aerobic respiration.
Glucose metabolized to acids only in presence of oxygen (yellow).

Pseudomonas,
Stenotrophomonas,
etc.




Fermentative metabolism

An anaerobic process.
Production of acids from glucose occurs with or without oxygen (yellow).

Enterobacteriales

Facultative Anaerobes

Oxidase Test



Tetramethyl-p-phenylenediamine dihydrochloride (colorless) is oxidized in the presence of cytochrome oxidase and oxygen to indophenol blue.

Oxidase Positive Non-fermenters

Pseudomonas aeruginosa
most other *Pseudomonas* species
Achromobacter
Burkholderia (wk)
Many others

Oxidase Negative Non-fermenters

Acinetobacter
Stenotrophomonas
Few others

Oxidase +; motile; MAC +

Oxidase+; non-motile; MAC +/-

Pseudomonas aeruginosa

Pseudomonas spp. (most)

Achromobacter

Alcaligenes

Burkholderia (wk ox)

Chryseobacterium

Flavobacterium

Sphingobacterium

Moraxella spp

Oxidase -; non-motile; MAC+

Acinetobacter lwoffii

Acinetobacter baumanii
complex

Oxidase -; motile; MAC +

Stenotrophomonas maltophilia

Non-fermenters can be hard to identify

- Conventional media for *Enterobacterales* don't identify; specialized biochemical media
- Most grow slowly and react weakly
- Commercial systems OK for ID of common spp.
- GLC of acid metabolites is useful
- 16S rDNA sequencing may be best
- MALDI TOF proving very good

Pseudomonas spp. - epidemiology

- Soil, water, plants, hospital environ, etc.
- Need moisture
- Prefer temp range 4° - 36°C; some grow at 42°C.
- Poor colonizer of healthy persons.
- *P. aeruginosa* is most virulent species

P. aeruginosa - Clinical Significance

- Infections of immunocompromised
- Swimmer's ear
- Wound infections
- Burns
- Ventilator associated pneumonia
- Cystic fibrosis lung infections
- Conjunctivitis & keratitis
- Bacteremia
- UTI, pneumonia, meningitis, osteomyelitis, endocarditis, etc.

Pseudomonas virulence factors

Antiphagocytic – alginate, altered LPS side chains, exoT

Motility – flagella

Adherence – pili, flagella (adhere to mucus), adhesins

Toxins –

- LPS endotoxin
- leukocidins, phospholipases, hemolysins.
- ExoS, ExoT, ExoU: alter host cell signaling, effect cytoskeleton/cytotoxic
- ExoA – blocks protein synthesis



Degradation of matrix proteins - proteases

Biofilm formation

Efflux pumps – remove antibiotics

Siderophores – scavenge iron for bacterial growth

Pseudomonas



- Straight or slightly curved; $0.5-1 \times 1.5-5 \mu\text{m}$
- Grape odor common; sometimes corn taco odor
- 1 or more polar flagella
- Usually oxidase +
- Pigments: pyoverdin, pyocyanin; pyorubin, pyomelanin (from *P. aeruginosa*.)

Pseudomonas species in clinical specimens

Fluorescent group (produce pyoverdin=fluorescein):

P. aeruginosa (42°C growth)

P. fluorescens

P. putida

P. veronii

P. monteilii

P. mosselii

Non-fluorescent group:

P. stutzeri

P. mendocina

P. pseudoalcaligenes

P. alcaligens

P. luteola (ox neg)

P. oryzihabitans (ox neg)


P. aeruginosa: metallic sheen, beta hemolysis, green or blue pigment




Pseudomonas generally grows in 1 – 2 days. CF cultures are held longer.

P. aeruginosa

Colonies can also be raised or mucoid.



Mucoid *P. aeruginosa*



Blood agar (mixed)



MacConkey agar

ASM MicrobeLibrary.org © Buxton

Biochemical identification of Pseudomonads

- Oxidase
 - Nitrate reduction & gas
 - Acetamide & citrate utilization
 - Gelatin hydrolysis
 - Arginine dihydrolase
 - Acid from carbohydrates by oxidation
-
- Previously combined biochemical analysis with GLC or sequencing

MALDI TOF MS

Burkholderia spp.


- >80 species
- Environmental niche: soil and water
- Opportunistic pathogens for humans and animals
 - *B. cepacia complex*
 - *B. gladioli*
 - *B. pseudomallei*
 - *B. mallei*
- Previously in *Pseudomonas* genus.

Burkholderia species Infections

- *B. cepacia complex*
 - pulm infection in cystic fibrosis & chronic granulomatous disease (CGD)
 - occasional opportunistic infections (UTI, septicemia, pneumonia, etc.)
- *B. gladioli* - infections in CF & CGD
- *B. pseudomallei* causes melioidosis
 - Pneumonia, abscesses, parotic abscess (children), osteo, septic arthritis, septicemia
- *B. mallei* - glanders in livestock
 - nodular lesions in the lungs and ulceration of the mucous membranes in the upper respiratory tract; septicemia and death

B. cepacia complex

- Oxidase pos; may be weak
- Colonies smooth & sl. raised
- May have dirt-like odor
- Pinkish on MAC after several days



ASM Image Atlas

Burkholderia cepacia complex

20 Genomospecies

Common species:

*B. multivorans**

*B. cenocepacia**

B. cepacia

B. vietnamiensis

B. contaminans

B. stabilis

B. dolosa

Speciate at reference lab.
MALDI TOF identifies to
complex.

Can be difficult to distinguish *B. cepacia* complex, & *B. gladioli*, *Pandoraea*, *Ralstonia*, & *Cupriavadis* by routine automated biochem tests & sometimes MALDI TOF

*50% of isolates in U.S. CF cases.

B. cepacia complex & CF

- Infection w/*B. cepacia* complex contraindication for lung tx.
- *B. cenocepacia* is probably most virulent.
- “Cepacia syndrome” in CF
Necrotizing pneumonia, respiratory failure & bacteremia
- Resistant to aminoglycosides; many antibiotics
- Therapy is challenging: ceftazidime, minocycline, meropenem, trim/sulfa, levofloxacin, cefiderocol

B. cepacia selective agars

(may require 3 days incubation)

OFPBL Selective Agar

Oxidation-
Fermentation
Polymixin B
Bacitracin &
Lactose;
Yellow colonies



BCSA – *B. cepacia* selective agar

Clear colony, agar around colony changes from red to yellow.

Contains lactose & sucrose, phenol red indicator, crystal violet to inhibit gram positives & gentamicin, vancomycin & polymixin B for additional selection.

Burkholderia pseudomallei

Soil & surface water; enters through abraded skin or inhalation

SE Asia, Africa, Americas; usually asymptomatic

Risk to: DM, ETOH, chronic renal or lung disease

Agent of melioidosis

- Pneumonia, abscesses, parotic abscess (children), septicemia, septic arthritis, osteo etc.

- Considered an agent of bioterrorism (BSL3)
- Small GNB w/bipolar staining on Gram stain. Wrinkled colonies.



B. pseudomallei on Ashdown agar

Burkholderia mallei

- Agent of glanders in livestock
- Not found in environment
- Africa, Asia, Middle East, C. and S. America
- Highly infectious
 - Can infect humans
- Inhalation leads to pneumonia
- Cutaneous infection leads to skin nodules, regional lymph node
- Disseminates to organs

Stenotrophomonas maltophilia

- Not a pathogen for healthy persons
 - Immunocompromised, ICU, IV Catheter, ventilator
- Often acquired from nosocomial sources: distilled water, nebulizers, dialysates, etc.
- Respiratory specimens; esp. cystic fibrosis patients (but not virulent)
- Other opportunistic infections

S. maltophilia

- Distinct violet-green colony on blood agar
- Oxidase negative
- Identified by biochems & MALDI TOF



<http://www.apa.uoit.ca/virtuallab/intro.php>

S. maltophilia –

A multiply drug resistant pathogen.

- Drug of choice = bactrim
(trimethoprim/sulfamethoxazole)
- Second: Minocycline/doxycycline/tigecycline*
- Some possible options:
 - Levofloxacin
 - Ticarcillin-clavulanate
 - Ceftazidime
 - Cefiderocol


Acinetobacter species

Natural Habitat & Clinical Significance


- Present in nature, food & hospital environment
- Survive in moist & dry environments.
- Weak pathogen in healthy individuals.
- *A. baumanii* commonly colonizes GI tract of ICU patients, but not healthy individuals
- Frequent cause of nosocomial infections:
 - Respiratory tract (VAP)
 - UTI
 - Wounds, severe infections in soldiers in Iraq
 - Hospital acquired infections lead to septicemia

Acinetobacter species

- Strictly aerobic; non-glucose fermenter
- 1-1.5 x 1.5-2.5 μm coccobacillary cells or short rods
- May be arranged in pairs
- Gram stain: can be hard to decolorize (appear purplish-pink)
- May appear slightly pink, smooth & opaque on MacConkey agar



ASM Microbe library



ASM MicrobeLibrary.org © Buxton

Acinetobacter speciation

A. baumanii complex or *A. baumanii/A. calcoaceticus* complex

Six species identified by MALDI TOF or commercial systems to the complex

2 Major groups based on carbohydrate oxidation

Saccharolytic – usually *A. baumanii* complex

Asaccharolytic – usually *A. lwofii* (usually v. susceptible to abx)

Acinetobacter baumanii complex susceptibility to antibiotics

- Susceptibility testing is needed for every isolate due to common resistance
- MDR – multi-drug resistance is common.
- CRAB – carbapenem-resistant *A. baumanii*. These often only susceptible to tigecycline, aminoglycoside, cefiderocol.
- A huge therapeutic challenge!

Intrinsic Resistance Summary

CLSI M100 Appendix B

Carbapenemases

- Carbapenemases can be acquired by some gram-negative bacteria
 - *Enterobacteriales* (e.g. KPC, NDM, OXA-48)
 - *Pseudomonas aeruginosa* (e.g. VIM)
 - *Acinetobacter baumannii* (e.g. OXA-23)
- Some gram-negative bacteria have intrinsic resistance to carbapenems due to carbapenemases (e.g. *Stenotrophomonas*)

Non-fermenter with Peritrichous Flagella

Alcaligenes xylosoxidans

- A pathogen in **Cystic Fibrosis patients**
- Can be a nosocomial pathogen in immunosuppressed hosts causing bacteremia and meningitis
- Oxidase +; catalase +; saccharolytic
- Grows well on MacConkey. Non-pigmented
- Usually resistant to: aminoglycosides, fluoroquinolones and first generation cephalosporins.

Elizabethkingia (Chryseobacterium) meningosepticum

- Non-motile; oxidase positive
- Can be yellow pigmented; weakly fermentative
- Contaminant in hospital fluids; can grow in antiseptics and disinfectants
- Endocarditis, septicemia, pneumonia & meningitis



Since 2011 *E. anophelis* has emerged as a cause of sepsis, meningitis, & pulm infection in U.S.

- Recent outbreaks
- May now be predominating *Elizabethkingia* species
- Found in midgut of mosquitos


Non-Fermenters can be pigmented

Methylobacterium species:


Gram stain: pleomorphic GNB w/vacuoles.; dry colony

Roseomonas species:

Gram stain: coccoid bacilli; wet, mucoid colony



Roseomonas, Bard JM 2010




Methylobacterium, Culture collection of Switzerland

Neisseria spp. & *Moraxella catarrhalis*

Neisseria and *Moraxella catarrhalis*

- Oxidase positive
- Gram-negative **diplococci**, adjacent sides flattened;
 - “coffee-bean”
- **Rod-shaped** *Neisseria* e.g. *N. elongata*, *N. weaveri* and rod-shaped *Moraxella* spp.
 - elongate w/penicillin exposure



Coccal *Neisseria* and *Moraxella* species

- *Neisseria gonorrhoeae*
- *Neisseria meningitidis*
- *Moraxella catarrhalis*
- Non-pathogenic *Neisseria* spp.
 - *N. lactamica*
 - *N. cinerea*
 - *N. flavaescens*
 - *N. subflava*
 - *N. sicca*
 - *N. mucosa*

Neisseria gonorrhoeae: Epidemiology

- Humans only natural host, no other known reservoir
- Not part of normal microbiota
- Carriage can be asymptomatic, particularly in women
- Transmission primarily by sexual contact
- CDC estimates 1.6 million new cases in 2018


Neisseria gonorrhoeae: gonorrhea

Male -

- Purulent discharge from urethra and dysuria after 2-7 day incubation
- Epididymitis, prostatitis, periurethral abscesses may occur

Women -

- Cervicitis
 - Vaginal d/c, dysuria, abdominal pain
- Ascending genital infections (salpingitis, tubovarian abscess, PID) in 10-20% of women



Neisseria gonorrhoeae: Disseminated disease

- 1-3% of infected women (lower incidence in men)
- From GU tract through blood to skin or joints
- Fever; migratory arthralgias; suppurative arthritis in wrists, knees, ankles
- Pustular rash - necrotic, grayish central lesion on erythematous base on extremities (not head and neck)



Neisseria gonorrhoeae: Other syndromes

- Anorectal gonorrhea
- Pharyngitis
- Ophthalmia neonatorum
 - Ocular infection acquired by neonate at birth
 - Lid edema, erythema, purulent discharge
- Perihepatitis
 - (Fitz-Hugh-Curtis syndrome)




Neisseria gonorrhoeae: Lab dx

❖ Specimen Collection: (fastidious)

- Dacron or rayon swabs
- No alginate or cotton
- Plate at bedside or use E swab or transport w/charcoal
- Jembec system

(GC Lect agar) – tablet generates moist 3-7% CO₂ atmosphere



Neisseria gonorrhoeae: Lab dx

❖ Culture:

Chocolate agar and
Selective medium:


- Mod Thayer-Martin (MTM) – vanc, colistin, nystatin, trimethoprim
- Martin-Lewis, NYC, GC-Lect - similar to MTM
- Incubate in 5% CO₂ enhanced, humid atmosphere for 48 hours



Neisseria gonorrhoeae: Lab dx

❖ Gram stain (GN intracellular diplococci)

- >90% sensitive and 98% specificity in men with purulent urethritis
- Only 60% sensitive in asymptomatic males
- Insensitive in women with cervicitis
- Unless intracellular, not specific in women
- Useful for arthritis



Neisseria gonorrhoeae: Lab dx

- Oxidase and catalase positive
- Produces acid by oxidizing glucose
- Commercial tests e.g.
 - Vitek NHI card
 - Rapid NH
 - API NH
- MALDI-TOF MS
- Culture replaced by NAAT



Gray to tan; can be raised, sticky

Neisseria gonorrhoeae: Lab dx

- Superoxal test – 30% hydrogen peroxide (not 3%)
- Almost all *Neisseria* spp. & *Moraxella* catalase pos (3% H₂O₂)
- Usually only *N. gonorrhoeae* give strong rxn; other *Neisseria* spp give weak rxn




Cystine-tryptic agar (CTA) carbohydrates for ID *Neisseria* species

1% of CHO and phenol red as indicator

- Glucose
- Maltose
- Lactose
- Sucrose

Replaced by rapid commercial systems



gluc, mal, lac, suc



N. gonorrhoeae



N. meningitidis



N. lactamica

BactiCard Neisseria

Butyrate esterase

- *M. catarrhalis*

Prolylaminopeptidase only

- *N. gonorrhoeae*

γ-glutamyl-aminopeptidase

- *N. meningitidis*

β-galactosidase

- *N. lactamica*




Rapid presumptive ID of
Neisseria spp. isolated from
selective media

Neisseria gonorrhoeae: Therapy

- Pen R due to β -lactamase production or altered PBP is now common
- Current recommendation:
 - Dual rx with Ceftriaxone + Azithromycin
- Dual therapy because many patients infected with both *N. gonorrhoeae* and *Chlamydia trachomatis*.


Fig 1. The percentage (%) of isolates with decreased susceptibility or resistance to extended-spectrum cephalosporin (ESC) (cefixime and/or ceftriaxone) according to the most recent World Health Organization (WHO) Gonococcal Antimicrobial Surveillance Programme (GASP) data (2014 for most countries, but for a few countries, only 2011–2013 data were available).



Wi T, Lahra MM, Ndowa F, Bala M, Dillon JAR, et al. (2017) Antimicrobial resistance in *Neisseria gonorrhoeae*: Global surveillance and a call for international collaborative action. PLOS Medicine 14(7): e1002344. <https://doi.org/10.1371/journal.pmed.1002344>

Neisseria meningitidis

- Gram negative diplococci
- Oxidase and cat positive
- Encapsulated
- Grows on Choc, BAP, MTM (modified Thayer-Martin) media
- Oxidative production of acid from glucose+maltose



Neisseria meningitidis: Epidemiology


- 12 serogroups – most infections A, B, C, W135, Y
 - B, C, Y predominate in Eur, Amer
 - A and W135 - developing countries
 - Y and W135 - pneumonia
- Humans only natural host
- Variation (1-40%) in nasopharyngeal carriage; highest for school age children and young adult
- Transient carriage with clearance after specific Ab develop
- Person-to-person spread via aerosolization of respiratory tract secretions

Neisseria meningitidis: Meningococcemia

Small petechial skin lesions on trunk and lower extremities are common, may coalesce to form larger hemorrhagic bullae




Thrombosis of small blood vessels with multiorgan involvement



Neisseria meningitidis: Meningococcemia

Tachycardia & hypotension can develop


Overwhelming DIC with shock, together with bleeding into adrenal glands may occur (Waterhouse-Friderichson syndrome)



25% fatality rate, even if treated

Neisseria meningitidis: Meningitis

- Abrupt onset with headache, neck rigidity, fever, confusion, photophobia (very young children may have nonspecific signs – fever, vomiting)
- Mortality approaches 100% in untreated; <10% mortality if promptly treated
- Neurologic sequelae – hearing deficits, arthritis



Neisseria meningitidis: Other Syndromes

Pneumonia - adults; mostly serogroup Y

Arthritis – following disseminated infection

Urethritis – emerging infection in MSM


Neisseria meningitidis: Lab dx

Meningitis:

cytospun gram
stain of CSF

Gram-negative
diplococci

May be
intracellular



ASM Image Atlas


Neisseria meningitidis: Lab dx

Inoculate chocolate and blood agar

N. meningitidis

- gray colony; imparts green color to agar immediately surrounding colony
- will grow on BAP

N. men on ML and MTM agars



Neisseria meningitidis: Lab dx

Risk of Lab Acquired Infection: Work with suspicious colonies in BSC

Oxidase positive

ID by MALDI TOF

Commercial kits: biochemical/enzymatic tests

Oxidatively acidifies glucose and maltose

Produce γ -glutamyl-aminopeptidase

Serogrouping at public health labs

Neisseria meningitidis: Therapy

Penicillin or ceftriaxone or carbapenem

Occ strains with decreased pen susceptibility
due to altered PBP – use ceftriaxone

Chloramphenicol if β -lactam allergic

Prophylaxis –

- Close contacts of cases
- rifampin, ciprofloxacin, or ceftriaxone

Neisseria meningitidis: Vaccines

Vaccine – A, C, W, Y

- 11-12 yr olds, booster at 16
- Microbiologists
- Travel to Africa
- Asplenic; complement deficiency

Serogroup B vaccine

- Recommended for 16-23 year olds
- Multiple doses for best protection

Moraxella (Branhamella) catarrhalis: Epidemiology

Since late 1970s – recognized as important and common resp tract pathogen


- Sinusitis (3rd after *S. pneumo*, *H. flu*)
- Otitis media (15-20%)
- Bronchitis and bronchopneumonia in patients with COPD [2nd most common cause of COPD exacerbations (30%) after *H. flu*]
- Pneumonia in elderly - 10% of CAP

Moraxella catarrhalis: Culture

- Grows well on 5% sheep blood, choc agar
- Prefer increased CO₂ atmosphere (3-7%)
- Colony appearance
 - gray to white, opaque, smooth appearance, 1-3 mm
 - Hockey puck consistency; colony may be moved intact over surface of agar
- Gram-negative diplococci



ASM MicrobeLibrary.org © Pfizer Inc.





[Bcatcols.jpg \(335×196\) \(cdc.gov\)](#)

Moraxella catarrhalis: Identification

Oxidase and catalase positive
Asaccharolytic

DNase test (agar with DNA and toluidine blue)

M. catarrhalis have enzyme butyrate esterase



Moraxella catarrhalis: Therapy

- Perform Beta-lactamase test
 - Most β -lactamase positive (pen & amp R)
- Susceptible to most other abx e.g. amoxicillin-clavulanate (Augmentin)
- AST not performed

Moraxella species other than *M. catarrhalis*


- Oxidase pos, nonmotile, asaccharolytic
- Gram neg coccobacilli or short broad rods
- Some strains may resist decolorization and appear gram-variable
- Grow well on 5% sheep blood agar and choc
- Elongate in presence of penicillin to distinguish from cocci



Questions?




NON-FERMENTER





The TSI Reaction

NON-LACTOSE FERMENTER



LACTOSE (SUCROSE) FERMENTER



Other *Neisseria* species

N. lactamica

N. cinerea (occ mis-ID as GC)

N. flavescens –yellow

N. sicca

N. mucosa

N. elongata – more bacillus shaped than other *Neisseria* spp

N. weaveri – bite wounds from animals, gram neg rod

